Edison Oncology

Executive Summary

Edison Oncology is a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2019 with a focus on developing first-in-class, small-molecule, biomarker-driven therapies for oncology. The company employs a capital-efficient strategy that combines internal discovery and development with strategic partnerships to address significant unmet medical needs. Its pipeline centers on novel small molecules with potent anti-tumor activity, targeting specific biomarkers to maximize efficacy and minimize toxicity. Currently, Edison Oncology's lead program is in Phase 1/2 clinical development, evaluating its candidate in biomarker-selected solid tumors. The company's approach aims to deliver precision medicine solutions, leveraging biomarker stratification to improve patient outcomes. As a private entity, Edison Oncology has not disclosed its total funding or valuation, but its disciplined R&D model positions it to advance its pipeline efficiently. With a strong scientific foundation and focus on high-unmet-need indications, the company is poised for potential value inflection points as it progresses its clinical programs and explores strategic collaborations to accelerate development and commercialization.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 interim efficacy and safety data readout for lead small-molecule program45% success
• Q1 2027Initiation of a Phase 2 trial in a second biomarker-defined indication60% success
• TBDAnnouncement of a strategic partnership or licensing deal for a pipeline asset50% success